Early Access — free while we kick the tires
EdgarHawk

Chee Conley

President & CEO

Director Officer
1 filing analyzed · 1 company · Latest 2024-09-12

Companies

Company Buys Sells Direction
Syros Pharmaceuticals, Inc. SYRS 2 0 Net buying

Activity

September 2024
high
Buy
100,000 shares
$160,680
Significance 6/10

CEO Chee Conley bought 100,000 shares (100.0K shares) for $160,680.00 at blended $1.61; stock down 80.0% from 52-week high.

Chee Conley, the President & CEO, executed 2 purchases totaling 100,000 shares for $160,680.00 between September 10–11, 2024, raising his holdings from 22,504 shares to 122,504 shares (+444.4%). The timing occurs after the stock has declined 80.0% from its 52-week high of $7.84 and is trading 18.2% lower over the past 30 days and 73.8% lower over 90 days. Syros remains unprofitable with net income of $-23,327,000.00 on quarterly revenue of $3,762,000.00 and faces a contraction headwind (annual revenue growth of -33.2%). The scale of the purchase—more than quadrupling the CEO's pre-transaction stake—during a period of steep price decline and operational losses suggests management is materially increasing exposure at a depressed valuation in its own stock.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access